Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Medicover, Audiocast, Q1'25

By Inderes4/29/2025, 7:30 AM
Medicover

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Fredrik Rågmark
00:00 - 19:13

Good morning, everyone, and welcome to the first quarter 2025 results presentation. And it's with great pride and joy that we present this report. In fact, I think it's probably the best report we have presented, possibly with the exception of one or two COVID-boosted pandemic reports. But in terms of the broad business, it is definitely the best report we have published since we listed the company now eight years ago. It's a combination of factors. You know, we see continued strong top-line growth. Organic growth was more than 14%. And most importantly, the further down the profit and loss statement you go, the more operational leverage you observe coming through in margins. Expanding EBITDA margin up 1.6 percentage points, EBIT margin up 2.4 percentage points. And, you know, it continues as you flow down through the profit and loss statement, which is exactly what we have been focused on. It is exactly what we have been reporting to you over the past 4 or 5 quarters. It is just that as the numbers get bigger, it becomes a bit more pronounced. And that's really what we see here. Uh, you know, Poland continues to be really very strong in healthcare services. Uh, now, India had a particularly weak quarter. And we'll speak a little bit more about that later on. But I think it's noteworthy to see that we pushed through these results, both in growth and margin expansion. Despite, actually, you can argue, a disappointing quarter out of one of our core markets, we still saw significant growth. So more about that a bit later. Diagnostics are very strong. Again, I remind you that half of diagnostics is in Germany, where a good chunk of that is public reimbursement, and we receive no price compensation. But despite that, with all the initiatives going on and actually really strong growth in the German private pay revenue and really good performance outside of Germany, in DX, we see really good growth, double-digit organic growth out of DX as well as margin expansion. Now that's flowing through, as you've seen in the last quarters in really good cash generation cash flow. You know we've always had good cash flow. It's just that the numbers start to get bigger, so the amounts become larger. And then also, I'm really very pleased and happy to be able to report to you that on a quarterly basis, i.e. We annualized the first quarter, we have. Achieved the year-end 2025 financial targets that we set a little bit more than two years ago. So we're on an annualized basis. We're trading on around €2.3 billion of organic revenue. We're just a tad above 350 million organic adjusted EBITDA. And we're also trading above those two additional targets. We added a year ago, adjusted EBITDA of at least 235 million and EBIT of at least 140 million. So that's after nine quarters out of 12. So, three quarters of the period. And for all of those that attended our Capital Markets Day, I think you very well remember that they were certainly not unambitious targets. I believe that demonstrates a super performance. Then, if you go on to our standard graphic pages. The revenue split is quite typical. What's worthwhile to point out there? You see, Poland has now grown into 52% of revenue on the back of its stellar growth performance over a longer period of time. You see 22% growth out of Poland, 7% out of Germany, which is not bad, in fact, because there is relatively no price growth and relatively little volume growth in the public pay segment. So the private pay segment is growing really well, with a 19% increase out of Romania. And you see basically a flattish 1% out of India. And I take the opportunity to comment on that here. Now, India had a strange first quarter. Uh, we were trading pretty much on plan in January and the first week of February. And then it was pretty much a cliff fall for the second half of February and March. And I think most people in India experienced the same thing. So very weak consumer sentiment. Then we have around 10% of medical tourism in our business in India, and we got no visas issued. So that sort of came to a halt. We closed down one underperforming unit, etc. . So there were a number of factors explaining that fact. But, you know, there's no other way of expressing the first quarter in India than it was a disappointment. Now, I think the most important of all is that it was an exceptional quarter. Now April is pretty much over, like tomorrow, and we are back and trading with significant double-digit revenue growth again in April, which we expect to continue going forward, which is important. So. So that is India. We then flip on to the perfect slide. We're very pleased with how the volume growth is translating into higher margins and consequently increased profitability. So EBITDA up to 86.5 million, 29% growth, and even 15% margin, showing good growth, 150 basis points on last year. And the adjusted number is above 90 million for the first time. So 90.6 million adjusted EBITDA, 15.7%. So good. Strong number, adjusted EBITDAaL up over 60 million. I think also, for the first time, effectively. And then I only mention EBIT is almost doubling, not fully doubling, but not far from it, from 19 up to 36 million, so a margin of 6.2%. So significant margin expansion. And again, very healthy. Good cash flow. And then of course, the biggest expansion, if you wish, comes on EPS, obviously, because it's the smallest number. So EPS more than tripling effectively from just above €0.04 to above €0.13. So I think it's a super, super performance. Then if you go to healthcare services, there is good growth running above 400 million, I think for the first time. So 403 million of revenue, 18% up of which 15% was organic and just short of 9% of that being price. So, I remind you that price is very important to us, ensuring we can continue to implement price growth to manage our operations effectively. Although, you know, cost inflation has certainly come down and we are in a much better position than a couple of years ago. But one should also be very clear on the fact that it's not gone. So it's not normalized. So it's really important that we are able to keep ensuring that we can continue to raise pricing, although at lower levels than what was seen last year. So fee-for-service here is half of the division, up 14%. And I made the point before that. You know, performance is pretty much stellar across everything we do in, uh, in Poland. Uh, it is also good actually out of Romania, relatively speaking, compared to last year, we still have loss-making units in the large hospital in Bucharest. But you know, Romania is pushing on. I have commented on India. The member growth may appear somewhat soft. I remind you that, as we announced at the end of last year, we are exiting the Hungarian business, and as we do that, it happens gradually throughout the first six months of the year. So we had a not insignificant negative member movement out of Hungary as part of that exit process here in the first quarter, which contributed quite significantly to that lower than normal member growth number. If we then switch to the earnings profile for healthcare services, we see strong margin expansion, in fact, super strong margin expansion. You see EBITDA up more than two percentage points, a bit even more. 2.3 percentage points, a bit, uh. Significantly more than doubling in terms of absolute amounts and almost also doubling in terms of the margin you see. 3.4 to 6.7. So lots of operational leverage is coming through here. And I remind you this is despite the Indian business, which is significant in this division, not firing on all cylinders in this particular quarter. So there's still room to improve this situation significantly as we progress. You actually see that in this next bullet point where we have reported that a number of times. Now, when we take the six most immature hospitals, five of them being in India and one of them being the large recent addition in Bucharest, you see that we had an EBITDA loss for the quarter of 3.9 million. Effectively, that's 600,000 worse than in the prior quarter, which is purely driven by the point I made on India. In fact, Romania is improving the situation. So the loss is coming out of the Indian hospitals due to lower revenue than we had in the prior quarter. But again, I reiterate that's going to reverse into the second quarter. So you don't need to worry about that going forward. But one should recognize that in this quarter, the medical cost ratio is the most important cost category in this business, i.e. All of the cost of delivering the medical service, you see, is actually down quite significantly, by two percentage points, which is a combination of factor mix, price growth, and a lot of very good hard work by our management team to manage utilization and costs. You have the standard Indian picture. Nothing has changed in that since we showed this the last quarter. Now we have to remind you we have two more units coming up in India over the coming 12 months. Both of them in the main Hyderabad market. So one will open in the summer. Both of them are large units. And the second one will open towards the end of the year or beginning of 2026. Then, flipping to diagnostic services again, I made the point before about the good revenue growth and strong momentum in this business. 182 million. So just short of 12%. Almost all of it being organic growth, with the price component just above 3% of this, which is slightly less than half of the price component in healthcare services. Again, you have heard me say many times before, that's explained by the fact that half of this business is in Germany, where there's very little price compensation. So basically, outside Germany, we have been able to adjust prices very much in line with how healthcare services have been able to do. So, good performance pretty much across all markets here, really. You see a relatively benign growth in lab tests. We have done fewer. If you remember, last year we conducted a significant number of nearly free lab tests in Ukraine for the public insurance house. We still do some of those tests, but we did significantly fewer this quarter, which explains the much lower lab test growth vis-à-vis revenue growth. Fee-for-service here accounts for a full 70% of the division, and it was up 16%. I remind you, we talked a lot about the end of last year about the pricing reform, the additional pricing reform, I should say, that came into force in Germany in January. We have assumed a worst-case scenario for us, and that's what we are accounting for. We will know in early July how the different Länder CVS treat this. And it may be that we get some upside. Time will tell. At least we know it's not going to get any worse than what we are assuming currently in our numbers. You can also see a little bit of what I'm talking about on these two pie charts to the right, where you see the upper pie chart, you see Germany is growing 6% and below. You see, public funding is increasing by 3%. And basically pretty much all of that public money is in Germany. So that means that the other half of the 6% growth in Germany is actually experiencing a 12% growth rate, if you see what I mean. So that illustrates the fact that our private pay German business is actually growing very nicely. Now, this resulted in a good flow-through to increased profitability. So EBITDA performed very well, showing a significant increase. So, a bit more than one percentage point, just short of a 20% margin. EBITDA, likewise, just short of a 16% margin. And EBIT then grew a bit more. So a margin of just above 12%, up 28%. So, uh, good results came out of this. Uh, and again, it's not split out here, but I think I made that comment last quarter around. I can make that comment again that actually, Germany, where there's a lot of focus, obviously on this price reform, etc. . Our total German business in diagnostics is growing its margins. So relative to the first quarter last year, despite all the pressures around us, we are up around one percentage point in terms of the German margin. Then we have two post-closing events that we just want to comment on. We made two acquisitions that we had sort of hinted to you about before in the previous quarter; these closed just early in April. Both of them had been in competition clearance for quite some time. So we were very happy when they finally got released. In diagnostics, you may be familiar with the relatively large lab group, SYNLAB Group, that used to be listed in Germany. Now, again, it's a private company, and they are selling off a number of assets. And we had an opportunity to pick up this set of markets, and this is really a synergy play for us. So we have tremendous synergies, particularly in Romania but also in Turkey. And then they have some really nice businesses in some of the other markets there in the Balkans. But you can see that we stated in the release that we expect, already within one year, to have grown their current profitability by at least 50%. And within at least two years we'll have doubled the current profitability levels from synergies, really. So we feel we have all of that under control. So we believe this is a very good, very strategic, and certainly very accretive acquisition for our shareholders. Then in healthcare services, we build further on the tremendous growth and positioning we have in Poland by adding a very well-run fitness operator to our network. And then I remind you, you know, we sell these sports cards in Poland alongside our healthcare cards to the B2B corporate clients. And then they are buying either standalone healthcare. They may be buying standalone sports, but increasingly they are buying a mix of the two, which is really what we want, because, of course, the more customers also go and look after themselves at the gym, the healthier they become, so the less illness they will contract. And hence the synergies are both in distribution and cost for us. So we expect this to be a very good acquisition. We think it's priced reasonably. We will have good synergies on the overlap that I was just talking about, and it also will be very accretive to our results. And with that, I think I hand over to Anand for the Financial Review.

Anand Patel
19:13 - 25:16

Thank you, Fredrik. Very pleasing to talk about another strong quarter for us. Um, and also, I would say it's a continuation of the story of recent quarters that we've spoken about. So, as per usual, I'll talk about EBITDA after lease costs, as these costs are a key part of our cash flow. So if you look at the group level, EBITDA grew to €60.4 million. That's a growth of 39% with a margin accretion of 1.8%. And the pleasing thing is, similar to what I said in Q4, the story is consistent across both business units. So we have strong absolute growth across both business units, both in price and in volume, and margin rate accretion across all businesses as well. In healthcare in particular. So we had EBITDA of 14 million. So a margin rate of 9.9%. So that was up 2.3% year on year. So really strong performance there, particularly as Frederic mentioned, given that the India performance was slightly below expectations, but back on track in diagnostics again despite the news about Germany, etc. . Fredrik mentioned that we grew volume, we grew price through expanding our fee-for-service business, and also we improved our margins. So overall EBITDA of 28.7 million in DS, with a margin rate up 1.2% year on year to 15.7%. So if we look at page 16, um, a key thing for us this quarter, I guess, was a real improvement in our leverage levels. So our loans payables were broadly unchanged from Q4. Uh, and clearly, uh, our EBITDA grew year on year. So that resulted in our leverage dropping to 3 from 3.4, which we had in Q4 last year. I will talk about future projections when we get to the target slide. But for now, really strong performance from a leverage perspective. But that's due to the timing of tax settlements in Poland. Uh, again, a strong performance from a cash perspective. Uh, again, reiterating what Fredrik said earlier. So net operating cash was up 11.6% to 87.5 million, predominantly driven by EBITDA and free cash flow, which in essence is cash flow after maintenance CapEx but before investment CapEx. That was up year on year as well to 44.2 million. And the final line I'll talk a little bit about is how ROIC was up pleasingly compared to what we reported in Q4. So in Q4, we were at 6.7%, and in Q1 this year, we're at 8.3%. And that's where you can really see the benefit of the EBIT accretion that we're seeing year on year. So Fredrik mentioned that EBIT was up, nearly doubling in Q1. And that really helps our ROIC level. So we're pleased to see that. And hopefully that's a manifestation of what will happen for the rest of the quarter. Rest of the year. Sorry. Uh, looking at CapEx. So from a CapEx perspective, we spent 28 million in Q1, which is broadly the same as last year. As a percentage, it was 5% of revenue. Previously, we've guided that our CapEx spend in FY25 will be between 5% to 6%. So, a bit of timing. We'll spend a little bit more later in the year. From a medical perspective, a small accretion in the month but broadly unchanged at 915,000 m². And then you have the two charts that we normally show at the bottom of the page. So on the left, you can see that actually, similar to last year's cash flow, we see a spike in Q1 from a free cash flow perspective and clear headroom between that and what we've invested in our business. From an investment CapEx perspective, on the right, you can see the Q1 breakdown of growth and maintenance CapEx, year on year. So the first block is the spend in Q1, FY 25. You can see the split is 53% growth and 47% maintenance. That's kind of just a timing thing. So going forward, we project for the full year, we'll be back to about the 60 over 40 levels that we've seen in prior years. In terms of splits, 60% is allocated for growth, and finally, we are talking about targets. So, Fredrik mentioned in his opening slide that our run rate is on track to beat all these targets. It's a message we've communicated in the last two quarters, and we're pleased to reiterate that in Q1 this year. So just to confirm, we will exceed our organic revenue target of 2.2 billion. We expect strong performance for the rest of the year. We expect to exceed our organic EBITDA target of 350 million. You've seen positive and consistent results over the past quarters in terms of price and volume improvements and margin accretion, so we anticipate a continuation of that trend for the remainder of the year. From a leverage perspective, in Q1, we were at three times as we realized and took in some loans to fund the acquisitions we made in April. We've mentioned before that we may be above the target of three and a half times for a short period of time. So please do not be surprised. If you see a slight, uh, increase above 3.5 in Q2. However, we expect levels to drop down to three and maybe slightly below three by the end of this year. So we expect to achieve that target. Fredrik has already mentioned that, in terms of the bottom left, the additional targets we've provided are to offer some assurance: EBITDA in excess of 235 million and EBIT in excess of 140 million. You know, I'm confident in saying that we can actually achieve those numbers as well. So, with that final record quarter for us, it's my honor to hand it back to Fredrik for the final slide.

Fredrik Rågmark
25:16 - 27:02

Thank you. Thank you. Alan. So, um. Yeah. Key takeaway. So, um, we have always grown well, and we keep growing well. And I think it's reasonable to assume that we will continue to grow well going forward as well. And I've just talked about the financial targets on a quarterly basis, annualized, having been achieved in this quarter, which, of course, is super good. Um, and importantly, it comes from a solid margin expansion in both divisions. So while some businesses obviously are stronger than others, it is quite uniform in terms of performance across everything we do. Uh, very good cash flow. We've always had very good cash flow. Again, it's just that the numbers get bigger, so it becomes a bit more visible. And the acquisitions are not visible in these numbers. They will be visible when John and Anand report in late July for the second quarter. And both of these acquisitions will be very accretive, as I mentioned. And they add about 80 odd million euros of annualized revenue together. Outlook remains strong and solid, and I am very happy. I'm very confident to hand over leadership to John and Anand and the leadership team. I think that's the takeaway. Thank you.

Unknown 1
27:13 - 27:14

And back to the operator.

Operator
27:14 - 27:31

Ask a question, please. Dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Mathias Madsen from Seb. Please go ahead.

Mathias Madsen
27:35 - 28:44

Yes. Good morning all. Um, so in your last quarterly conference call, I just wanted to take the opportunity to say congrats. Really, on an incredible and impressive journey with, uh, Medicover. Fredrik. It's been fun to work with you from my perspective. So with that, I have three questions. And first, it might be a longer one, but I'm just trying to understand a bit better what is going on in healthcare services. Um, so the six units you've been referring to are close to 4 million negative on EBITDA, as you said during the presentation, actually reflecting a higher loss. Um, also a softer quarter in India and margins coming this strong. So maybe explain what positive drivers have been kicking in during Q1 compared to the last couple of quarters, where the margin improvement has been smaller? And also, do you expect or do you anticipate this positive margin trend to continue in healthcare services going forward? That's the first one. And then I will take two more.

Fredrik Rågmark
28:45 - 31:02

Yeah, yeah. So, Mathias, you know, the margin expansion is coming from the businesses that I say are standing out, and that's really from Poland. So the employer-paid business had a stellar quarter in terms of margin expansion. Uh, you know, I made the point that the medical loss ratio is actually down year on year. And given the size of that business, a percentage point or two reduction in the medical loss ratio has a big impact on that business. Uh, now we have significant growth in our adjacent sports business, which is a good margin business. So the more we grow that, you know, the mix is slightly improving. And the third element, which one tends to forget, is that when we look at the situation, Romania is a good example. But you have a very significant improvement year on year. So that sort of swing factor, when you go from an outright loss-making position to perhaps a small positive position, makes a big difference on the margin. So that's really what you see here, Matias. So, a number of factors are being driven by the business that perform very well. And you know, that's not going to change. So that's why I made the comment initially that it's noteworthy to see that we have this performance despite the fact that the losses from these six units are actually increasing relative to the prior quarter.

Mathias Madsen
31:06 - 31:43

And this makes sense. Thanks for that. Um, then you're taking me into my next question a little bit here. So I appreciate you not commenting on margins per business segment, but I think it looks like in your report recently that your sports business, as you alluded to, and the ophthalmology business are growing very fast. So could you give us a sense of how these two areas together compare to the overall healthcare service business area in terms of margin profiles? Is this possible?

Fredrik Rågmark
31:45 - 32:09

I mean, you know, the sport and gym business is a higher margin business than the health business. I guess we can say that. And then, you know, the fact that it's growing so fast is because we have bought and invested quite significantly in that area over the past few years.

Unknown 2
32:09 - 32:12

Three years. So it is.

Fredrik Rågmark
32:12 - 32:13

Not that strange.

Unknown 2
32:13 - 32:14

That it's growing like that.

Mathias Madsen
32:17 - 32:54

I agree, I agree. Then the third one is concerning Germany. So if you could talk about the split between private and public. And also, I mean, the growth rate seems to be quite extraordinary in the private part. Um, I have, I mean, just some thoughts. Is it the private and public capacity? Is there not enough capacity, you know, or has capacity been reduced due to deteriorating profitability, or, you know, what is happening there? I think, yeah, this is important to cover because it looks quite extraordinary.

Fredrik Rågmark
32:56 - 33:47

You have exactly the same thing happening in Germany that has been occurring in this country, Sweden, for a long time now. When the public system starts to run out of budgets, you know they're not going to tell you they've run out of money. You know, you're just going to get your appointment much further down in time. So accessibility goes down. That's what happens when funding becomes scarce in the public system. And that's very much what we see in Germany. So on balance, more people who are covered by the public health insurance system will tend to pay privately to get a quicker appointment.

Unknown 2
33:48 - 33:48

Uh.

Fredrik Rågmark
33:49 - 34:29

You know, that we didn't see a number of years ago in Germany, but that you see now, and I think that's a core part of explaining the higher growth in private pay in Germany. Um, so, you know, that is the difference when you look at how come you're growing like that, where basically the public pay piece, which is significant, has very low volume growth and no price growth. So you correctly observe, Mathias, that then the other half must be growing quite significantly.

Mathias Madsen
34:32 - 34:33

Thank you very much for this.

Operator
34:39 - 34:43

The next question comes from Philipp Ekengren from ABG. Please go ahead with your question.

Philipp Ekengren
34:46 - 35:05

Hi all, and thanks for taking my question. And again, congrats on a strong quarter here. Um, I just want to loop back to the Polish market. You write that the growth rate in Polish hospitals, similar to Indian hospitals, has experienced some difficulties in Q1. Uh, could you elaborate a bit on that, please?

Fredrik Rågmark
35:07 - 35:50

Uh, yeah, I wouldn't overdo that, Philip. Uh, you know, it's, uh, you know, some quarters, some businesses are strong. In other quarters, other businesses are strong. And this particular quarter, our Polish hospital business was slightly behind plans, unlike in the previous quarter. In the fourth quarter, it was the opposite. So it is just a factor to note. Do you know what has been driving performance this quarter? We wouldn't expect it to be the same next quarter. Just to give you that sort of indication. So, it's a factor in quarter one. But it's not something that you should expect to continue.

Philipp Ekengren
35:52 - 36:13

Um, I just want to loop back to the Polish market. Thank you very much. That's clear. Uh, and then on the acquisition of SYNLAB Group operations, can you say anything about what type of labs are they? Are they more of a simple character or are they more advanced labs? And also, maybe if you care to explain a bit on what type of synergies you're planning to realize, and also maybe update us on what processes you're looking to implement there.

Fredrik Rågmark
36:15 - 37:26

Yeah, I mean, they would have very similar labs to ours. You know, there are six standalone country operations. So they would operate, you know, their lab network very similarly to how we would do. You know, it's a very professionally well-invested business. So nothing much different. We may have different machines because we may work with different sorts of key vendors, but otherwise the labs would be very similar. So, the key synergies really come from closing down infrastructure. So when you operate in the same geographic market, you don't need two labs, and you don't need two BDPs next to each other. So there's a lot of overlapping infrastructure that you don't need. So, you know, when we talk synergies, it's pure cost synergies. So you can operate the combined business at much less than the current combined cost.

Philipp Ekengren
37:29 - 37:32

Yeah, that makes sense. Thank you very much. That was all for me for now.

Operator
37:35 - 37:39

The next question comes from Christopher Lilienberg from Carnegie. Please go ahead.

Christopher Lilienberg
37:44 - 38:43

Thank you. Uh. Three questions. Uh, first, on the diagnostics side, can you describe a little bit more about the growth outside of Germany? Is that mainly in Romania, or do you also see strong growth for more specialized tests that are sent from other countries into the German labs? Uh, my second question, um, is about the weakness in India that you mentioned. How much would you say is company-specific for Medicover, and how much of the weakness this quarter is due to the overall market? And then finally on the targets, could you provide a figure on the amount of sales that has been acquired since the target was first announced? Thank you.

Fredrik Rågmark
38:44 - 38:48

Could you please repeat the last one? Christopher. I didn't hear you correctly.

Christopher Lilienberg
38:50 - 39:00

Yes. I wonder how much sales have been added from acquisitions since the financial targets were first announced.

Fredrik Rågmark
39:02 - 39:12

Okay, Hanna will work that out while I, uh, I think it's 2 million only in this quarter, but we'll come back to it. So I'll start with the first one. Um.

Anand Patel
39:13 - 39:34

I can discuss diagnostic sales. So I think not just in Germany, but actually across all targets and all areas, we saw positive double-digit growth in terms of revenue from a diagnostics perspective.

Unknown 3
39:38 - 39:39

Can you remind us of your second question, please?

Anand Patel
39:41 - 39:43

Can you remind us of your second question, please? Sorry.

Christopher Lilienberg
39:45 - 39:50

I was wondering about what seems like a temporary weakness here in India. How much.

Unknown 4
39:50 - 39:52

Of that was not company specific.

Christopher Lilienberg
39:52 - 40:08

Specific. You mentioned some issues at a hospital. And how much was the weekly market? And if you have any view about the reason for this market weakness and the sharp uptick again in April.

Fredrik Rågmark
40:09 - 41:51

So, um, there's no scientific answer to that question. Christopher. So if you allow me, I'll just give a personal guesstimate. And I don't know if John will agree with me or not, but I sense probably about two thirds of the weakness is due to our own actions. And one-third of the weakness was due to much weaker consumer sentiment than expected for half of the period, something like that. In terms of what impacted us mostly regarding internal matters, it was the lack of visas for admitting and making arrangements for traveling patients from abroad. Um, uh, and then, uh, you know, why, uh, why did we see this, uh, consumer weakness in India, principally in the second half of the first quarter? And, uh, I don't think there's one single answer, at least in my understanding, despite having read quite a bit. So I think quite a few factors sort of came together. It will be interesting to see. I mean, we're the first in the Indian publicly listed hospital peer group to report. So it will be interesting to see when those reports come out, how they comment on this. I think it was probably more pronounced in the southern part of the country where we are, as opposed to the northern part of the country around Delhi. Uh, but again, that will be interesting to see when the other companies report.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…